文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

比阿培南对敏感及利福平耐药结核分枝杆菌的体内外活性

In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

本研究评估碳青霉烯类抗生素比阿培南与利福平联用对低水平和高水平利福平耐药结核分枝杆菌的体内外协同作用。体外棋盘滴定显示对H37Rv和低水平耐药株115R有协同,但小鼠模型中仅对H37Rv协同,对两株耐药株未见协同。比阿培南单药对三株菌均有活性,提示其作为抗结核药物(包括耐药结核)的再利用潜力。

要点

  • 比阿培南与利福平体外对H37Rv和低水平利福平耐药株115R有协同作用。
  • 小鼠模型中比阿培南/利福平仅对H37Rv协同,对高、低水平利福平耐药株均无协同。
  • 比阿培南单药对药物敏感株及两株利福平耐药株均有体内活性。

核心结论

  • 比阿培南具有作为抗结核药物的潜力,包括用于利福平耐药结核的治疗。
  • 比阿培南有望被重新定位为治疗耐药结核急需的「新」药。

研究设计与样本

  • 临床前研究,体外采用棋盘滴定法评估比阿培南/利福平协同作用
  • 使用三株结核分枝杆菌:低水平利福平耐药株115R、高水平利福平耐药株124R和药物敏感亲本株H37Rv
  • 小鼠模型中先进行比阿培南对H37Rv的剂量范围实验,再评估比阿培南/利福平对每株菌感染小鼠的活性

主要发现

  • 体外,比阿培南与利福平对H37Rv和115R株显示协同作用。
  • 体内,比阿培南对H37Rv呈明确剂量依赖性活性,所有剂量活性等于或高于利福平单药。
  • 小鼠模型中比阿培南和利福平对H37Rv有协同杀菌活性;对两株利福平耐药株感染小鼠未观察到协同。
  • 比阿培南单药对全部三株菌均有活性。

临床怎么用

  • 比阿培南单药对敏感及利福平耐药结核分枝杆菌均有体内活性,支持进一步临床前开发。
  • 比阿培南/利福平协同仅见于敏感株和低水平利福平耐药株体外,对耐药株体内无协同。
  • 比阿培南的临床抗结核应用尚需后续临床研究验证。

局限性

  • 为临床前研究,结果尚需临床验证。
  • 协同作用仅在体外对H37Rv和115R观察到,体内仅对H37Rv观察到,对耐药株未见协同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biapenem, a carbapenem antibiotic, has been shown to have synergistic bactericidal anti-TB activity when combined with rifampicin both in vitro and in the mouse model of TB chemotherapy. We hypothesized that this synergy would result in biapenem/rifampicin activity against rifampicin-resistant Mycobacterium tuberculosis . OBJECTIVES: Our objective was to evaluate the synergy of biapenem/rifampicin against both low- and high-level rifampicin-resistant strains of M. tuberculosis , in vitro and in the mouse model. METHODS: Biapenem/rifampicin activity was evaluated using three strains of M. tuberculosis : strain 115R (low-level rifampicin resistance); strain 124R (high-level rifampicin resistance); and the drug-susceptible H37Rv parent strain. Biapenem/rifampicin synergy was evaluated in vitro by chequerboard titration. In vivo , we first conducted a dose-ranging experiment with biapenem against H37Rv in the mouse model. We then evaluated biapenem/rifampicin activity in mice infected with each M. tuberculosis strain. RESULTS: In vitro , synergy was observed between biapenem and rifampicin against H37Rv and strain 115R. In vivo , biapenem exhibited clear dose-dependent activity against H37Rv, with all biapenem doses as active or more active than rifampicin alone. Biapenem and rifampicin had synergistic bactericidal activity against H37Rv in the mouse model; no synergy was observed in mice infected with either of the rifampicin-resistant strains. Biapenem alone was active against all three strains. CONCLUSIONS: Our preclinical experiments indicate that biapenem has potential for use as an anti-TB drug, including for use against rifampicin-resistant TB. Thus, biapenem has promise for repurposing as a 'new' - and desperately needed - drug for the treatment of drug-resistant TB.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Kaushik A, Ammerman NC, Tasneen R, et al. In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother. 2017. PMID: 28575382. doi:10.1093/jac/dkx152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。